Literature DB >> 25670544

Radiation therapy planning for early-stage Hodgkin lymphoma: experience of the International Lymphoma Radiation Oncology Group.

Maja V Maraldo1, Bouthaina S Dabaja2, Andrea R Filippi3, Tim Illidge4, Richard Tsang5, Umberto Ricardi3, Peter M Petersen6, Deborah A Schut6, John Garcia2, Jayne Headley4, Amy Parent5, Benoit Guibord5, Riccardo Ragona3, Lena Specht6.   

Abstract

PURPOSE: Early-stage Hodgkin lymphoma (HL) is a rare disease, and the location of lymphoma varies considerably between patients. Here, we evaluate the variability of radiation therapy (RT) plans among 5 International Lymphoma Radiation Oncology Group (ILROG) centers with regard to beam arrangements, planning parameters, and estimated doses to the critical organs at risk (OARs).
METHODS: Ten patients with stage I-II classic HL with masses of different sizes and locations were selected. On the basis of the clinical information, 5 ILROG centers were asked to create RT plans to a prescribed dose of 30.6 Gy. A postchemotherapy computed tomography scan with precontoured clinical target volume (CTV) and OARs was provided for each patient. The treatment technique and planning methods were chosen according to each center's best practice in 2013.
RESULTS: Seven patients had mediastinal disease, 2 had axillary disease, and 1 had disease in the neck only. The median age at diagnosis was 34 years (range, 21-74 years), and 5 patients were male. Of the resulting 50 treatment plans, 15 were planned with volumetric modulated arc therapy (1-4 arcs), 16 with intensity modulated RT (3-9 fields), and 19 with 3-dimensional conformal RT (2-4 fields). The variations in CTV-to-planning target volume margins (5-15 mm), maximum tolerated dose (31.4-40 Gy), and plan conformity (conformity index 0-3.6) were significant. However, estimated doses to OARs were comparable between centers for each patient.
CONCLUSIONS: RT planning for HL is challenging because of the heterogeneity in size and location of disease and, additionally, to the variation in choice of treatment techniques and field arrangements. Adopting ILROG guidelines and implementing universal dose objectives could further standardize treatment techniques and contribute to lowering the dose to the surrounding OARs.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25670544     DOI: 10.1016/j.ijrobp.2014.12.009

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  ISRT: a new radiation therapy for malignant lymphomas: Introduction to the review article by Specht and Yahalom.

Authors:  Keisuke Sasai; Masahiko Oguchi
Journal:  Int J Clin Oncol       Date:  2015-07-11       Impact factor: 3.402

Review 2.  The concept and evolution of involved site radiation therapy for lymphoma.

Authors:  Lena Specht; Joachim Yahalom
Journal:  Int J Clin Oncol       Date:  2015-07-07       Impact factor: 3.402

Review 3.  Optimal Therapy for Early-Stage Hodgkin's Lymphoma: Risk Adapting, Response Adapting, and Role of Radiotherapy.

Authors:  Andrea Riccardo Filippi; Mario Levis; Rahul Parikh; Bradford Hoppe
Journal:  Curr Oncol Rep       Date:  2017-05       Impact factor: 5.075

4.  On the Importance of Individualized, Non-Coplanar Beam Configurations in Mediastinal Lymphoma Radiotherapy, Optimized With Automated Planning.

Authors:  Linda Rossi; Patricia Cambraia Lopes; Joana Marques Leitão; Cecile Janus; Marjan van de Pol; Sebastiaan Breedveld; Joan Penninkhof; Ben J M Heijmen
Journal:  Front Oncol       Date:  2021-04-15       Impact factor: 6.244

5.  High burden of subsequent malignant neoplasms and cardiovascular disease in long-term Hodgkin lymphoma survivors.

Authors:  Simone de Vries; Michael Schaapveld; Frederika A van Nimwegen; Katarzyna Jóźwiak; Pieternella J Lugtenburg; Laurien A Daniëls; Judith M Roesink; Richard W M van der Maazen; Wouter E M Kok; Berthe M P Aleman; Flora E van Leeuwen
Journal:  Br J Cancer       Date:  2018-01-30       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.